Physician profile
Jay L Blake
NPI 1619284742
$4,910.25
in general payments reported to CMS, 2019-2025
20 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $567 · 2023: $1,147 · 2024: $1,966 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,423 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.51 |
| Education | $326.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,012.40 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $612.29 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $521.19 | 2021-2023 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $441.91 | 2021-2024 | Winlevi, Absorica Ld |
| Genzyme Corporation | $394.03 | 2022-2024 | |
| Abbvie INC. | $329.02 | 2021-2024 | |
| Ucb, INC. | $325.17 | 2023-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $271.94 | 2022-2025 | Dupixent |
| Pfizer INC. | $267.09 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $172.16 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $112.73 | 2023-2024 | Olumiant, Taltz, Zepbound |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Incyte Corporation | $78.50 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $66.35 | 2025 | Adbry |
| Amgen INC. | $58.85 | 2023-2024 | Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Galderma Laboratories, L.P. | $43.51 | 2024-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $23.79 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2023 | Spevigo |
| Royal Biologics, INC. | $22.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.